Latest Dexcom Inc (DXCM) Headlines Upcoming Conferences,

New Post Public Reply Private Reply Replies (0) Message Board

Mar 13, 2014 at 7:48 AM

Latest Dexcom Inc (DXCM) Headlines

Upcoming Conferences, Financial Results, New Products, and Awareness Campaigns - Analyst Notes on Align Technology, LabCorp, Insulet, CareFusion, and DexCom
PR Newswire - Tue Mar 11, 8:20AM CDT
Today, Analysts Review released its analysts' notes regarding Align Technology, Inc. (NASDAQ:ALGN), Laboratory Corp. of America Holdings (NYSE:LH), Insulet Corporation (NASDAQ

ODD), CareFusion Corporation (NYSE:CFN), and DexCom, Inc. (NASDAQ

XCM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Dexcom Supports NASCAR Driver Ryan Reed's American Diabetes Association Drive to Stop Diabetes(SM) Initiative
Business Wire - Wed Mar 05, 3:04PM CST
Dexcom, Inc., (NASDAQ

XCM), the leader in continuous glucose monitoring (CGM), announced today it is supporting NASCAR driver Ryan Reed and the American Diabetes Association's Drive to Stop Diabetes(SM) national diabetes awareness initiative. As part of the campaign, Dexcom will support Ryan Reed and the Association's Drive to Stop Diabetes presented by Lilly Diabetes to build awareness about the importance of daily monitoring and tracking of glucose trends in the management of diabetes.

Is DexCom (DXCM) a Great Growth Stock? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 7:48AM CST
DexCom can be a promising growth stock in the Medical Instruments industry space backed by significant rise in estimates and strong potential for outperformance

Insider Trading Alert - WAB, DXCM And CMCSA Traded By Insiders
at The Street - Fri Feb 28, 10:45AM CST
Stocks with insider trader activity include WAB, DXCM and CMCSA

DexCom Beats, Sees Narrower Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 8:40AM CST
Owing to narrower reported loss or adjusted earnings in the 2013-fourth quarter, shares of Dexcom rose 3.5% since the announcement of earnings results

DexCom Announces Upcoming Conference Presentations
Business Wire - Tue Feb 25, 7:30AM CST
DexCom, Inc. (NASDAQ

XCM) today announced that management will present an update on DexCom at the following upcoming investor conferences:

U.S. Bancorp Asset Management, Inc. Announces March Distributions for Closed-End Funds
Business Wire - Fri Feb 21, 11:15AM CST
The closed-end funds listed below, which are advised by U.S. Bancorp Asset Management, Inc. (NYSE:USB), today declared their March distributions. The distributions will be allocated on a per-share basis on the common stock. The distributions have an ex-dividend date of March 3, 2014 and will be paid on March 19, 2014 to shareholders of record on March 5, 2014.

DexCom, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Thu Feb 20, 3:01PM CST
DexCom, Inc. (Nasdaq: DXCM) today reported its audited financial results as of and for the quarter and fiscal year ended December 31, 2013.

Can the Rally in DexCom (DXCM) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 7:57AM CST
Can the Rally in DexCom (DXCM) Shares Continue?

Teleflex Recalls Tracheal Tube - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 1:50PM CST
Teleflex Medical has announced a worldwide voluntary recall of its ISIS HVT Tracheal Tube.

Cepheid Down to Strong Sell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 2:20PM CST
On Feb 4, Zacks Investment Research downgraded Cepheid to a Zacks Rank #5 (Strong Sell).

The Zacks Analyst Blog Highlights:Henry Schein, Cyberonics, DexCom, Regeneron Pharmaceuticals and Bayer
PR Newswire - Tue Feb 11, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Henry Schein Inc. (Nasdaq:HSIC-Free Report), Cyberonics Inc. (Nasdaq:CYBX-Free Report), DexCom, Inc. (Nasdaq

XCM-Free Report), Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN-Free Report) and Bayer (OTC:BAYRY-Free Report).

Top 3 MedTech Stocks, Poised to Gain on Earnings - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 11:41AM CST
This hike is expected to result in 385 million new grant opportunities for researchers.

Fluidigm Corporation (FLDM) Crumbles: Stock Falls by 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 7:30AM CST
The shares of Fluidigm Corporation fell over 6% on the day.This reverses the most recent uptrend for the company, as the stock is now up almost 8% since Jan 29.This scientific instruments company has seen a flat track record when it comes to current year estimate revisions.

FDA Approval for DexCom's G4 PLATINUM - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 4:10PM CST
DexCom G4 PLATINUM gets FDA approval for use in children affected with diabetes aged between 2 and 17 years.

DexCom Schedules Fourth Quarter and Full Year 2013 Earnings Release and Conference Call for February 20, 2014 at 4:30 p.m. Eastern Time
Business Wire - Thu Feb 06, 7:30AM CST
DexCom, Inc. (NASDAQ

XCM) today announced that it plans to release its fourth quarter and full year 2013 financial results after market close on Thursday, February 20, 2014. Management will hold a conference call to review the company's fourth quarter and full year 2013 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com by navigating to "About," then "Investor Relations," and then "Events and Webcasts," and will be archived there for future reference.

DexCom to Present at Leerink Global Healthcare Conference 2014
Business Wire - Thu Feb 06, 7:30AM CST
DexCom, Inc. (NASDAQ

XCM) today announced that Steve Pacelli, Executive Vice President, Strategy and Corporate Development, will present an update on the company at the Leerink Global Healthcare Conference 2014 in New York, New York on Thursday, February 13, 2014 at 1:25pm (EST). The presentation, which will occur live at The Waldorf Astoria, will be concurrently webcast.

DXCM: Improving the Quality of Life for Children With Diabetes
at The Street - Wed Feb 05, 7:38PM CST
A major FDA approval for Dexcom's continuous glucose monitor (CGM) device for children with diabetes was announced a couple of days ago, and this is one such event that will revolutionize the industry and improve the quality of life affecting so many...

'Mad Money' Lightning Round: Staying Away From Valero Energy
at The Street - Wed Feb 05, 5:00AM CST
Cramer's no fan of Activision Blizzard but he does like Zoetis.

Jim Cramer's 'Mad Money' Recap: What's a Stock Gotta Do to Get Some Love?
at The Street - Tue Feb 04, 7:17PM CST
For a stock to rally it must beat on the top line, the bottom line and raise guidance to impress Wall Street -- and even then its not guaranteed, Cramer complains.

DexCom Inc. (DXCM) Stock Research Links

DXCM Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Moore Law Urges Millrose Investors: Join the Action

Is Millrose Playing a Risky Game? When I caught wind of this latest debacle with Millrose Properties, Inc. (NYSE: MRP), my gut reaction was a mix of curiosity and skepticism. Hunterbrook Media's report just blasted across the headlines, digging up some dirt on Millrose's recent financial maneuvers. Apparently, these cats have been busy buying homes to the tune of $200...

TilePix Expands into Walmart with Nail-Free Decor Launch

TilePix Makes Big Moves with Walmart TilePix is launching their new line of nail-free wall décor at Walmart—this ain’t your grandma’s wall art. This company's bringing their magnetic, nail-free wizardry to retail stores nationwide for the first time, and they’ve chosen a real heavyweight partner—Walmart. What comes in the package? Well, they’re dealing in...

AAI Rolls Out Agency Gauge: AI-Driven Insights Platform

Bringing Artificial Intelligence to the Insurance Table Affordable American Insurance (AAI) is shaking things up in the insurance world with their new tool, Agency Gauge. Picture this: you're running an independent agency, neck-deep in data, and this AI-powered marvel swoops in and turns those confusing numbers into actionable business insights. It's like having a wise...

DOCS Faces Investor Legal Battle for Alleged Misconduct

The DOCS Predicament: Investors Facing Class Action Doximity, Inc., trading as NYSE:DOCS, finds itself in hot water again as shareholders gear up for a legal skirmish over alleged securities fraud. Schall, Brown & Schwartz LLP, the firm rallying the shareholders, has fired the opening salvo, pointing fingers at Doximity for cooking the books about their Newsfeed’s...

Roof Inspections: Richmond's Key to Home Longevity

Inspect, Protect, and Forget Your Worries Homeowners in the Greater Richmond area wisely take to heart the old saying: an ounce of prevention is worth a pound of cure. But let's cut through the noise for a moment and zero in on a foundational truth: regular roof inspections are not a luxury—they're an absolute must. Roofing expert Seth Brown, from BNH Roofing, makes it...

AI-Designed Antivirals: A Brave New World

Pushing the Boundaries with AI in Drug Discovery It seems some smart folks over in South Korea are giving the pharma game a fresh twist, pitting artificial intelligence against viral invaders in a newfangled brawl. Professors from Korea University have managed to blend AI's computing prowess with good ol' lab doggedness to sniff out potential antiviral compounds. The...

Kansai Medical Ushers in New Era of Cancer Research

Breaking Ground in Cancer Treatment Trials I've seen some thrilling breakthroughs in my time following the pharmaceutical industry, but what Kansai Medical University and Daiichi Sankyo are doing elevates the game. They're rolling out the first patient dose of DS1025 in Osaka, Japan—a move that marks the onset of a global Phase 1 clinical trial. This is no ordinary...

2GenPen & LordCap Team Up: Game-Changer in ABS?

New Kids on the Structured Credit Block? Well, it looks like we're in for a ride with 2GenPen teaming up with Lord Capital to shake up the asset-backed securities (ABS) world. They're strutting their stuff by launching a strategic collaboration to boost credit analysis. Think of it as a power-up for ABS transactions—because nobody loves a murky credit rating. The Heart...

Ama La Vida's New Coaching: More Than a Financial Plan

Breaking the Retirement Myth Retirement ain't just about sailing off into the sunset with a fat wallet. What happens when the honeymoon period of the "golden years" ends and you're left pacing the floorboards, unsure of what comes next? Enter Ama La Vida's fresh approach to retirement coaching, tackling the side of retirement that's rarely spoken about: identity,...

Endava Faces Securities Fraud Lawsuit: Investor Implications

Endava in Hot Water Over Alleged Misleading Statements Alright, folks, gather around—there's a storm brewing over at Endava with shareholders mightier than the Greek gods, furrowing their brows with intent. You see, Schall, Brown & Schwartz LLP, a firm that practically eats legal challenges for breakfast, is beating the drums of a securities fraud lawsuit. Yep, I'm...